已发表论文

人类生长激素制剂的发展:缓释、延长的半衰期,新型注射装置和可供选择的给药途径

 

Authors Cai Y, Xu M, Yuan M, Liu Z, Yuan W

Published Date July 2014 Volume 2014:9(1) Pages 3527—3538

DOI http://dx.doi.org/10.2147/IJN.S63507

Received 4 March 2014, Accepted 17 April 2014, Published 25 July 2014

Abstract: Since the availability of recombinant human growth hormone (rhGH) enabled the application of human growth hormone both in clinical and research use in the 1980s, millions of patients were prescribed a daily injection of rhGH, but noncompliance rates were high. To address the problem of noncompliance, numerous studies have been carried out, involving: sustained-release preparations, prolonged half-life derivatives, new injectors that cause less pain, and other noninvasive delivery methods such as intranasal, pulmonary and transdermal deliveries. Some accomplishments have been made and launched already, such as the Nutropin Depot® microsphere and injectors (Zomajet®, Serojet®, and NordiFlex®). Here, we provide a review of the different technologies and illustrate the key points of these studies to achieve an improved rhGH product.
Keywords: intranasal, pulmonary, transdermal, microsphere, microneedle, hydrogel